It is critical for patients with relapsed CLL to have ibrutinib as the backbone of their treatment plan and in the management of their disease, Chanan-Khan explains. Ibrutinib is found to be effective because it improves progression-free and overall survival.

In a recent study examining the combination of ibrutinib with bendamustine and ritxuimab in patients with CLL and SLL, no safety concerns were observed. Therefore, ibrutinib can be seen as a well-tolerated and safe agent for patients, Chanan-Khan adds.

It is critical for patients with relapsed CLL to have ibrutinib as the backbone of their treatment plan and in the management of their disease, Chanan-Khan explains. Ibrutinib is found to be effective because it improves progression-free and overall survival.

In a recent study examining the combination of ibrutinib with bendamustine and ritxuimab in patients with CLL and SLL, no safety concerns were observed. Therefore, ibrutinib can be seen as a well-tolerated and safe agent for patients, Chanan-Khan adds.